UCSF-Mount Zion
Welcome,         Profile    Billing    Logout  
 33 Trials 
49 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Palefsky, Joel
ANCHOR, NCT02135419: Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions

Completed
3
4446
US
imiquimod, Aldara, IMQ, R 837, fluorouracil, 5-fluorouracil, 5-Fluracil, 5-FU, Efudex, infrared photocoagulation therapy, infrared coagulation, IRC, thermal ablation therapy, laser therapy, therapy, laser, clinical observation, observation, laboratory biomarker analysis
AIDS Malignancy Consortium, National Cancer Institute (NCI), The Emmes Company, LLC, University of Arkansas, University of California, San Francisco, University of Arizona
Anal Cancer, High-grade Squamous Intraepithelial Lesion, HIV Infection, Human Papilloma Virus Infection
08/21
03/24
NCT02059499: Imiquimod, Fluorouracil, or Observation in Treating HIV-Positive Patients With High-Grade Anal Squamous Skin Lesions

Active, not recruiting
3
91
US
imiquimod, Aldara, IMQ, R 837, fluorouracil, 5-fluorouracil, 5-Fluracil, 5-FU, questionnaire administration, laboratory biomarker analysis
AIDS Malignancy Consortium, National Cancer Institute (NCI), The Emmes Company, LLC, University of Arkansas
Anal Intraepithelial Neoplasia, High-grade Squamous Intraepithelial Lesion, HIV Infection
12/23
04/25
anal HSIL HIV-, NCT05555862: Artesunate Suppositories for the Treatment of HIV-negative Patients With Intra-anal HSIL

Active, not recruiting
2
17
US
Artesunate, Artesunic acid, dihydroartemisinin (DHA), artemisinin, Placebo
Frantz Viral Therapeutics, LLC, Amarex CRO, University of California, San Francisco, Anal Dysplasia Clinic MidWest, Laser Surgery Care
Anal High Grade Squamous Intraepithelial Lesion, Anal Precancerous Condition, AIN 2/3, HPV Infection, Anal Dysplasia, HPV Disease
12/24
12/24
ULACNet-104, NCT06651957: Anal High-risk HPV, HSIL, and Microbiome Among Hispanic Peoples Living With HIV (PLWH)

Recruiting
N/A
100
US, RoW
Biospecimen Collection, Specimen Collection, Questionnaires, Study-related questionnaires
University of California, San Francisco, National Cancer Institute (NCI)
Human Immunodeficiency Virus, Human Papillomavirus-Related Anal Squamous Cell Carcinoma, High-Grade Squamous Intraepithelial Lesions
05/26
12/26
CAMPO-101, NCT05074264: Screening Algorithms for Cervical and Anal High-Grade Squamous Intraepithelial Lesions in People With HIV in Mexico and Puerto Rico

Recruiting
N/A
1500
US, RoW
Biopsy, Biospecimen Collection - Anal, Biological Sample Collection, Biospecimen Collection, Biospecimen Collection - Cervical, Colposcopy, High Resolution Anoscopy, HRA, Imaging Technique, Diagnostic Imaging Technique, Imaging, Imaging Procedures, Medical Imaging
University of California, San Francisco, National Cancer Institute (NCI), US-Latin American-Caribbean HIV/HPV-Cancer Prevention Clinical Trials Network (ULACNet)
AIDS-Related Anal Carcinoma, AIDS-Related Cervical Carcinoma, High Grade Anal Intraepithelial Neoplasia, High Grade Cervical Intraepithelial Neoplasia, HIV Infection
12/24
12/24
NCT04142385: Incidence of HIV Infection in Screening Indian Men Who Have Sex With Men

Not yet recruiting
N/A
150
US, RoW
Cytology Specimen Collection Procedure, Cytologic Sampling, Laboratory Biomarker Analysis, Medical Examination, Exam, Examination, Medical Assessment, Medical Exam, Medical Inspection, Physical Examination, Assessment, Physical, Physical Assessment, Physical Exam, Proctoscopy with Biopsy, Questionnaire Administration
AIDS Malignancy Consortium, National Cancer Institute (NCI), Tata Memorial Hospital, Udaan Trust, University of Arkansas
HIV Infection
12/27
12/29
NCT04142398: Incidence of HPV Infection and HPV-Associated Disease in Screening Indian Men Who Have Sex With HIV-Positive Men

Not yet recruiting
N/A
246
US, RoW
Cytology Specimen Collection Procedure, Cytologic Sampling, High Resolution Anoscopy with Biopsy, High Resolution Anoscopy-Monitored Biopsy, Laboratory Biomarker Analysis, Medical Examination, Exam, Examination, Medical Assessment, Medical Exam, Medical Inspection, Physical Examination, Assessment, Physical, Physical Assessment, Physical Exam, Questionnaire Administration
AIDS Malignancy Consortium, National Cancer Institute (NCI)
HIV Infection, Human Papillomavirus Infection, Human Papillomavirus-Related Carcinoma
12/27
12/29
NCT06055868: People Living With HIV, Oral and Oropharyngeal Cancer, and Health Equity

Not yet recruiting
N/A
144
US
Group Meeting (Focus Group), Questionnaires
University of California, San Francisco, National Institute of Dental and Craniofacial Research (NIDCR)
HIV Infections, Oral Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma
11/29
11/29
Rosenberg, Jonathan
COMPASS-CD, NCT04809363: A Study of CDPATH™ to Help Manage and Treat Crohn's Disease

Active, not recruiting
4
200
US
CDPATH™, PROSPECT, Blood Draw
Takeda
Crohn's Disease
10/25
06/26
NCT06045754: A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease

Recruiting
4
150
Canada, US
Vedolizumab, Entyvio, Adalimumab, Humira, Ustekinumab, Stelara
Takeda
Crohn's Disease
06/27
06/27
NCT06095128: A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)

Recruiting
4
65
Canada, US
Vedolizumab, Entyvio, MLN0002, Tofacitinib, Xeljanz, CP-690, CP-550
Takeda
Ulcerative Colitis
07/27
07/27
ABX464-105, NCT05507203: ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1

Recruiting
3
612
Europe, Canada, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
03/25
04/25
ABTECT, NCT05535946: - Maintenance

Recruiting
3
1050
Europe, Canada, Japan, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
01/26
01/30
BAYOU, NCT03459846 / 2017-004556-27: A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer

Checkmark From BAYOU trial in combination with Imfinzi for urothelial cancer at ASCO-GU 2022
Feb 2022 - Feb 2022: From BAYOU trial in combination with Imfinzi for urothelial cancer at ASCO-GU 2022
Active, not recruiting
2
154
Europe, Canada, US, RoW
Durvalumab, Olaparib, Placebo
AstraZeneca
Urinary Bladder Neoplasms
10/20
12/24
CA209-9DJ, NCT03520491: A Study to Test the Safety of Immunotherapy With Nivolumab Alone or With Ipilimumab Before Surgery for Bladder Cancer Patients Who Are Not Suitable for Chemotherapy

Recruiting
2
45
US
Nivolumab, Ipilimumab, Radical cystectomy
Memorial Sloan Kettering Cancer Center
Bladder Cancer
01/26
01/26
EV-ECLIPSE, NCT05239624: Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer

Recruiting
2
23
US
Enfortumab vedotin, Pembrolizumab
Memorial Sloan Kettering Cancer Center, Astellas Pharma US, Inc., Seagen Inc., Merck Sharp & Dohme LLC
Urothelial Carcinoma
06/26
06/26
NCT05868265: A Study of Enfortumab Vedotin in People with Urothelial Carcinoma of the Upper Urinary Tract

Recruiting
2
24
US
Enfortumab Vedotin, Radical surgery
Memorial Sloan Kettering Cancer Center, Astellas Pharma US, Inc.
Urothelial Carcinoma
05/25
05/25
ACR-368-201, NCT05548296: A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma

Recruiting
1/2
390
US
ACR-368, prexasertib, Gemcitabine, OncoSignature
Acrivon Therapeutics, GOG Foundation
Platinum-resistant Ovarian Cancer, Endometrial Adenocarcinoma, Urothelial Carcinoma
07/26
12/27
NCT05585879: Demonstrating Effective Salvage of Inadequate Colonoscopies

Terminated
N/A
16
US
Pure-Vu EVS
Motus GI Medical Technologies Ltd
Colorectal Screening
04/24
04/24
NCT02657486: BGJ398 in Non-Muscle-Invasive Urothelial Carcinoma of the Bladder

Active, not recruiting
N/A
4
US
BGJ398
Memorial Sloan Kettering Cancer Center
Bladder Cancer, Non-Muscle-Invasive Urothelial Carcinoma
01/26
01/26
Ko, Andrew
NCT04056988: tSCI Contrast Enhanced Ultrasound Study

Completed
4
9
US
Perflutren Lipid Microsphere, DEFINITY®
University of Washington
Acute Spinal Cord Injury
11/23
11/23
RESET-RA, NCT04539964: Vagus Nerve Stimulation for Moderate to Severe Rheumatoid Arthritis

Active, not recruiting
3
243
US
Implant Procedure, Surgical placement of vagus nerve stimulator inside the neck, Conventional Synthetic DMARD, Background therapy with conventional synthetic DMARD, Active stimulation, Non-active stimulation
SetPoint Medical Corporation
Rheumatoid Arthritis
05/24
10/27
A021806, NCT04340141: Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer

Recruiting
3
352
Canada, US
Oxaliplatin, Irinotecan Hydrochloride, Leucovorin Calcium, Fluorouracil, Resection, Questionnaire Administration
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Pancreatic Adenosquamous Carcinoma, Resectable Pancreatic Adenocarcinoma, Pancreatic Cancer
01/26
11/30
Precision Promise, NCT04229004: A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer

Active, not recruiting
3
825
US
Gemcitabine combined with nab-paclitaxel, Dose -mFOLFIRINOX, Dose - Pamrevlumab combined with gemcitabine and nab-paclitaxel, Dose- Canakinumab and Spartalizumab combined with nab-paclitaxel and gemcitabine, Drug: Dose -SM-88
Pancreatic Cancer Action Network
Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma
06/27
06/27
PLATINUM, NCT06115499: The Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer

Recruiting
2/3
100
US
Nab paclitaxel, ABI-007, Abraxane, Albumin-bound Paclitaxel, Protein-bound Paclitaxel, Gemcitabine, Cisplatin, Magnetic Resonance Imaging, MRI, Computed Tomography, CAT Scan, CT Scan, Biospecimen Collection
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Pancreatic Acinar Cell Carcinoma, Pancreatic Adenocarcinoma, Pancreatic Adenosquamous Carcinoma, Pancreatic Carcinoma, Pancreatic Ductal Adenocarcinoma, Pancreatic Squamous Cell Carcinoma, Stage IV Pancreatic Cancer AJCC V8
01/29
12/29
NCT05221320: Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies

Terminated
2
47
US
Ulixertinib, BVD-523, BVD523, Hydroxychloroquine
BioMed Valley Discoveries, Inc
Tumor, Solid, Gastrointestinal Cancer
05/24
07/24
DisTinGuish, NCT04363801: A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer

Hourglass Oct 2023 - Mar 2024 : Q4'23/Q1'24 - Initial ORR data from DisTinGuish trial for 2L gastric cancer
Oct 2023 - Dec 2023: Initial data from part C of DisTinGuish trial in combination with tislelizumab for 1L gastric cancer
Checkmark Updated data from part B of DisTinGuish trial in combination with tislelizumab for 2L gastric cancer
Nov 2022 - Nov 2022: Updated data from part B of DisTinGuish trial in combination with tislelizumab for 2L gastric cancer
Checkmark ORR, PFS and OS data from DisTinGuish trial in combination with tislelizumab for gastroesophageal junction cancer or gastric cancer
More
Active, not recruiting
2
232
Europe, US, RoW
DKN-01 300mg, DKN-01 600mg, DKN-01 400mg, Tislelizumab 200mg, Tislelizumab 400mg, Oxaliplatin, Capecitabine 1000mg/ m2 BID, Xeloda, Leucovorin Calcium, Folinic acid, Fluorouracil
Leap Therapeutics, Inc., BeiGene
Gastric Cancer, Gastric Adenocarcinoma, GastroEsophageal Cancer
06/25
12/25
NCT05249101: A Study of Ivaltinostat Plus Capecitabine or Capecitabine in Metastatic Pancreatic Adenocarcinoma

Recruiting
1/2
70
US
Ivaltinostat, Capecitabine, Xeloda
CG Pharmaceuticals, Inc
Metastatic Pancreatic Adenocarcinoma
02/26
06/26
RAMP205, NCT05669482: Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer

Recruiting
1/2
40
US
avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel, Gemzar, Abraxane
Verastem, Inc.
KRAS Activating Mutation, Metastatic Cancer, Pancreas Cancer, Neoplasms Pancreatic, Malignant Neoplasm of Pancreas
05/25
12/25
THREAD, NCT03825289: Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer

Recruiting
1
39
US
Hydroxychloroquine, Trametinib, GSK1120212, JTP-74057, MEK Inhibitor GSK1120212, Mekinist
University of Utah, Novartis Pharmaceuticals
Metastatic Pancreatic Carcinoma, Stage II Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer, Unresectable Pancreatic Carcinoma
01/25
01/26
BCI, NCT01198964: Optimization of Human Cortical Stimulation

Recruiting
N/A
8
US
Low-level cortical stimulation
University of Washington
Epilepsy, Brain Injury
08/23
08/23
NCT03289572: Microgrid II - Electrocorticography Signals for Human Hand Prosthetics

Recruiting
N/A
20
US
University of Washington
Epilepsy Intractable
12/23
12/24
Butowski, Nicholas A
ACTION, NCT05580562: ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the Study)

Calendar Jan 2026 - Dec 2026: Final data from ACTION trial for newly diagnosed H3 K27M-mutant diffuse glioma
Calendar Jan 2025 - Mar 2025: Interim data from ACTION trial for newly diagnosed H3 K27M-mutant diffuse glioma
Recruiting
3
450
Europe, Canada, Japan, US, RoW
Dordaviprone (ONC201), Dordaviprone (ONC201) + Placebo, Placebo
Chimerix
H3 K27M, Glioma
08/26
08/26
GBM AGILE, NCT03970447 / 2020-002250-24: A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

Calendar Jan 2030 - Dec 2030: Market entry for glioblastoma
Oct 2023 - Dec 2023: Top-line data from GBM AGILE trial for glioblastoma
Recruiting
2/3
1030
Europe, Canada, US, RoW
Temozolomide, Temodar, Temodal, Temcad, Lomustine, CCNU, CeeNU, Gleostine, Regorafenib, Stivarga, BAY 73-4506, Radiation, Paxalisib, GDC-0084, VAL-083, Dianhydrogalactitol, VT1021, Troriluzole, BHV-4157, ADI-PEG 20, Pegargiminase
Global Coalition for Adaptive Research, Bayer, Kazia Therapeutics Limited, Kintara Therapeutics, Inc., Biohaven Pharmaceuticals, Inc., Vigeo Therapeutics, Inc., Polaris Group
Glioblastoma
06/26
06/28
SURVIVE, NCT05163080: SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma

Active, not recruiting
2
247
US
SurVaxM
MimiVax, LLC, Translational Drug Development, Merit
Newly Diagnosed Glioblastoma
08/24
08/24
NCT04762069 / 2021-003659-40: A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme

Hourglass Jan 2023 - Jun 2023 : Data from trial for glioblastoma
Hourglass Jul 2022 - Dec 2022 : Interim analysis data from trial for glioblastoma in adults
Active, not recruiting
2
210
Europe, US
Berubicin, Berubicin Hydrochloride, Lomustine, Lomustine Capsules, CCNU, CeeNU, Gleostine
CNS Pharmaceuticals, Inc., Worldwide Clinical Trials
Glioblastoma Multiforme, Adult
12/24
03/25
NCT05503797 / 2022-000627-20: A Study to Assess the Efficacy and Safety of FORE8394 in Participants with Cancer Harboring BRAF Alterations

Recruiting
2
250
Europe, Canada, US, RoW
Plixorafenib, FORE8394, PLX8394, Cobicistat, TYBOST(R)
Fore Biotherapeutics, Fore Biotherapeutics
Cancer Harboring BRAF Alterations
06/25
08/26
NCT05753007: A Clinical Trial of a Hemp-Derived, High Cannabidiol Product for Anxiety in Glioblastoma Patients

Recruiting
2
36
US
Cannabidiol (CBD), Placebo
Mclean Hospital, University of California, San Francisco, Center for Medicinal Cannabis Research
Glioblastoma
09/25
09/25
DIET2TREAT, NCT05708352: A Phase 2 Study of the Ketogenic Diet Vs Standard Anti-cancer Diet Guidance for Patients with Glioblastoma in Combination with Standard-of-care Treatment

Recruiting
2
170
US
Keto Diet, Standard Anti-Cancer Diet
Cedars-Sinai Medical Center, National Cancer Institute (NCI)
Glioblastoma Multiforme
06/28
06/29
ST101-101, NCT04478279 / 2019-004213-13: A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors

Active, not recruiting
1/2
125
Europe, US
ST101, Temozolomide, Radiation
Sapience Therapeutics
Glioblastoma, Melanoma Stage IV, Breast Cancer, Prostate Cancer, Glioblastoma Multiforme, GBM, Brain Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Prostate Cancer, Melanoma Recurrent, Prostate Cancer Metastatic, Recurrent Glioblastoma, Newly Diagnosed Glioblastoma
12/24
12/25
NCT06504381: DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma

Not yet recruiting
1/2
70
US
DB107-RRV, Toca 511, Vocimagene amiretrorepvec, DB107-FC, Toca FC, Extended-release 5-fluorocytosine, 5-fluorocytosine, Radiation Therapy (RT), Radiation Treatment, Temozolomide, Temozolomide (TMZ), Magnetic Resonance Imaging (MRI), MR, MRI, Surgical resection, Surgical tumor resection, Brain surgery
Nicholas Butowski, California Institute for Regenerative Medicine (CIRM)
High Grade Glioma, MGMT-Unmethylated Glioblastoma, MGMT-Methylated Glioblastoma
01/40
01/40
TNG908-C101, NCT05275478 / 2021-005605-27: Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors

Active, not recruiting
1/2
192
Europe, US
TNG908
Tango Therapeutics, Inc., Tango Therapeutics, Inc.
Locally Advanced Solid Tumor
04/25
09/25
NCT05370508: A Study of Sonodynamic Therapy Using SONALA-001 and Exablate 4000 Type 2.0 in Subjects With Recurrent GBM

Terminated
1/2
8
US
SONALA-001 (ALA) and MR-Guided Focused Ultrasound device (MRgFUS), Exablate Type 2.0
SonALAsense, Inc.
Recurrent GBM
06/24
07/24
NCT02022644: Study of Convection-Enhanced, Image-Assisted Delivery of Liposomal-Irinotecan In Recurrent High Grade Glioma

Completed
1
18
US
nanoliposomal irinotecan, MM-398, ONIVYDE
University of California, San Francisco, Ipsen, National Cancer Institute (NCI)
High Grade Glioma
12/20
05/23
NCT02924038: A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG)

Terminated
1
14
US
IMA950, IMA950 peptides, poly-ICLC, Hiltonol, Varlilumab, CDX-1127
Nicholas Butowski, Celldex Therapeutics, National Cancer Institute (NCI)
Glioma, Malignant Glioma, Astrocytoma, Grade II, Oligodendroglioma, Glioma, Astrocytic, Oligoastrocytoma, Mixed
12/22
12/22
FRONTIER, NCT05303467: A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM

Active, not recruiting
1
12
US
TheraSphere GBM, TheraSphere™ GBM Y-90 Glass Microspheres (TheraSphere GBM)
Boston Scientific Corporation
Glioblastoma Multiforme, Recurrent Glioblastoma
12/24
06/25
NCT04656535: AB154 Combined with AB122 for Recurrent Glioblastoma

Recruiting
1
46
US
Zimberelimab, Domvanalimab, Placebo
Yale University, National Cancer Institute (NCI), Arcus Biosciences, Inc.
Glioblastoma
02/25
12/25
NCT05557292: RMC-5552 Monotherapy in Adult Subjects with Recurrent Glioblastoma

Recruiting
1
48
US
RMC-5552, mTORC1/4EBP1
Nicholas Butowski, Revolution Medicines, Inc., National Cancer Institute (NCI)
Glioblastoma, Recurrent Glioblastoma
12/25
12/25
Jay, Naomi
NCT02059499: Imiquimod, Fluorouracil, or Observation in Treating HIV-Positive Patients With High-Grade Anal Squamous Skin Lesions

Active, not recruiting
3
91
US
imiquimod, Aldara, IMQ, R 837, fluorouracil, 5-fluorouracil, 5-Fluracil, 5-FU, questionnaire administration, laboratory biomarker analysis
AIDS Malignancy Consortium, National Cancer Institute (NCI), The Emmes Company, LLC, University of Arkansas
Anal Intraepithelial Neoplasia, High-grade Squamous Intraepithelial Lesion, HIV Infection
12/23
04/25

Download Options